Predominant but silent C1q deposits in mesangium on transplanted kidneys - long-term observational study

Takahiro Kanai 1,2*, Yuko Akioka 1,3, Kenichiro Miura 1, Masataka Hisano 1, Junki Koike 4, Yutaka Yamaguchi 5 and Motoshi Hattori 1

Abstract

Background: C1q nephropathy (C1qN) was first described as glomerular disease characterized by predominant mesangial C1q deposits in patients with proteinuria and no evidence of systemic lupus erythematosus. Several studies, however, revealed the clinical heterogeneity of C1qN, showing some cases with normal urinalysis. To confirm the existence of cases with predominant mesangial C1q deposits and negative or mild proteinuria and/or hematuria, we investigated renal graft biopsy specimens showing negative to mild proteinuria (less than or equal to 1+ by dip stick test) and/or hematuria.

Methods: Eligible participants were kidney transplant cases who corresponded to the criteria for C1qN and were followed more than 10 years. Their medical records were reviewed to determine the age at detection of predominant mesangial C1q deposits, gender, original renal disease and reason for renal graft biopsy, blood pressure, degree of proteinuria and hematuria, and serum creatinine levels.

Results: From 414 cases in adults and children, five pediatric patients (the male to female ratio, 1:1.5) were eligible. At the time when predominant mesangial C1q deposits were detected, 2 cases presented with mild proteinuria without hematuria, but the other 3 cases showed normal urinalysis. Light microscopy revealed minor glomerular abnormality in all the cases. Immunofluorescent study showed predominant mesangial C1q deposits with IgG, IgM and C3 in all cases. All selected specimens presented electron dense-depos in the mesangium. Ten years later from the detection, 2 cases continued to be normal urinalysis and 3 cases had mild proteinuria without hematuria. During this follow-up period, no cases presented with persistent proteinuria and/or hematuria greater than or equal to 2+ by dip stick test. And no cases developed systemic lupus erythematosus. Follow-up renal graft biopsies were performed once in 2 cases 8 years later from the detection. They showed minor glomerular abnormalities. C1q deposit disappeared in one case. In another case, immunofluorescent study was not examined.

Conclusions: This long-term observational study on transplanted kidneys confirms the existence of cases with predominant but silent C1q deposits in the mesangium who have negative or mild proteinuria.

Keywords: C1q nephropathy, C1q deposits, Clinicopathologic study, Protocol renal graft biopsy, Renal transplantation

* Correspondence: tkanai@jichi.ac.jp
1Department of Pediatric Nephrology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan
2Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
C1q nephropathy (C1qN) was described by Jennette and Hipp in 1985 [1, 2]. It is characterized by the following criteria: (i) the presence of predominant or co-dominant mesangial C1q deposits detected by immunofluorescence microscopy (IF), (ii) corresponding mesangial or para-mesangial electron-dense deposit (EDD), and (iii) absence of clinical and serological evidence of systemic lupus erythematosus (SLE). Clinically, patients have proteinuria in the nephrotic range and it is resistant to steroid treatment.

Clinicopathologic findings of C1qN have accumulated from various reports [3–5]. One study identified some cases with normal urinalysis and predominant mesangial C1q deposits [6].

To confirm the existence of cases with predominant mesangial C1q deposits and negative to mild proteinuria and/or hematuria, we investigated cases with renal graft biopsied specimens who had negative to mild proteinuria and/or hematuria.

Methods
Selection criteria
We investigated 414 serial cases with negative to mild proteinuria (less than or equal to 1+ by dip stick test) and/or hematuria (less than or equal to 1+ by dip stick test) who received renal transplantations. Renal graft biopsy specimens from cases were obtained between 2002 and 2005 at the Kidney Center in Tokyo Women’s Medical University. The cases consisted of 334 adults aged 19 years old or older, and 80 children aged 2 to less than or equal to 18 years. There were 242 males and 172 females.

Cases were selected if they had predominant mesangial C1q deposits (2+ or greater on a ± 4 scale) by the definition of C1qN [1, 2, 6], and if the follow-up period was more than 10 years since the predominant C1q deposits were detected. We excluded cases with morphologic features of membranoproliferative glomerulonephritis type I [1, 6] or that fulfilled the diagnostic criteria for SLE [7] because they showed mesangial C1q deposits.

Clinical data and laboratory results
The patients’ medical records were reviewed, noting the age at detection of predominant mesangial C1q deposits, gender, original renal disease, reason for renal graft biopsy, and blood pressure levels. The laboratory results for the following tests were also reviewed: degree of proteinuria and hematuria, anti-C1q antibody titers, and serum creatinine levels. Additionally, data on medications was collected including use of steroids, immunosuppressants, angiotensin receptor blockers (ARBs), and angiotensin converting enzyme inhibitors.

Pathologic findings
All specimens were examined by light microscopy (LM; hematoxylin-eosin, periodic acid-Schiff, and periodic-methenamine silver), IF (polyclonal rabbit anti-human IgG, IgM, IgA, C1q, and C3 antibody, Dako, Denmark), and electron microscopy (EM) according to standard techniques. Each glomerular tissue specimen was available for all three methods of evaluation for the detection of predominant mesangial C1q deposits. The degree of IF staining was graded as − (negative), ± (trace), 1+ (mild), 2+ (moderate), 3+ (marked), and 4+ (heavy) according to Jennette’s criteria [1, 2, 6].

Results
Eligible cases, clinical data, and laboratory results
Five pediatric patients (the male to female ratio, 1:1.5) at selection met the criteria for C1qN [1, 2, 6]. Samples from these 5 patients constituted 0.01% of all samples investigated.

The original renal diseases consisted of renal hypoplasia, focal segmental glomerulosclerosis (FSGS), autosomal recessive polycystic kidney disease, Alport syndrome, and chronic tubulointerstitial nephritis. All 5 patients received kidney transplantation (kidneys donated by their living parents) at a mean age of 8.8 years (SD 2.2). Reasons for renal graft biopsies at the time when predominant C1q deposits were detected were due to protocol in 4 cases, and mild proteinuria in 1 case (Table 1). Protocol renal graft biopsies were carried out an average of 2.2 times (range, 1 to 3 times) before predominant mesangial C1q deposits were detected. No case presented with hypertension [8] or signs or symptoms of infection when predominant mesangial C1q deposits were detected. The follow-up period after the detection of predominant C1q deposits ranged from 10 to 11 years.

When predominant mesangial C1q deposits were detected, 2 cases presented with mild proteinuria (1+ by dipsticks) without hematuria, but the other 3 cases showed normal urinalysis results (Table 1).

All eligible cases had anti-C1q antibody titers in the normal range (reference anti-C1q antibody titer, less than 2.2 μg/mL) [9]. 4 cases had normal serum creatinine levels and stable renal function. One case had a moderate increase in serum creatinine level (from 0.5 to 1.2 mg/dL) due to acute rejection 11 months after renal transplantation. After that, the patient maintained stable renal function.

During the follow-up period, no cases presented with persistent proteinuria and/or hematuria greater than or equal to 2+ by dip stick test. Additionally, no cases presented with hypertension or developed SLE.

These 5 patients were given immunosuppressive agents against rejection as follows: tacrolimus hydrate (adjusted to
target level of 3–5 ng/mL), mycophenolate mofetil (700 mg/m²/day), and methylprednisolone (1 to 4 mg/day).

At the time of diagnosis, 2 cases had received an ARB, losartan potassium, at 100 mg/day or 25 mg/day, respectively. All cases had received ARBs 10 years after the predominant C1q deposits were detected (Table 2). No cases had received angiotensin converting enzyme inhibitors at the time of detection of predominant mesangial C1q deposits or 10 years later.

Pathologic findings
Details of LM, IF EM findings are presented in Table 1. Averages of 28 glomeruli (10 to 63 glomeruli) were observed with LM; all these glomeruli showed minor glomerular abnormalities (MGA) (Table 1, Fig. 1a).

IF revealed predominant mesangial C1q deposits and co-deposits (Table 1, Fig. 1b). C1q deposits were limited to the mesangium or para-mesangium areas, except for 1 case whose specimen also exhibited staining in some capillary loops. Equal or less intense mesangial IgG, IgM, and C3 deposits were detected in all selected specimens (Table 1). IgA deposits were observed only in 1 case.

All selected specimens showed EDDs in the mesangium on EM (Table 1, Fig. 1c). Subendothelial deposits were observed in 1 case and subepithelial deposits were observed in 2 cases. No specimens showed tubuloreticular inclusions or foot process effacements.

Two cases had biopsies of their native kidneys before renal transplantation, but did not present with mesangial C1q deposits and EDDs. Renal graft biopsy specimens from transplanted kidneys at renal transplantation in these 5 cases were absent of C1q deposits and EDDs.

In 2 cases, follow-up renal graft biopsies after C1q detection on mesangium were performed once 8 years later in case (Table 2). Their glomeruli presented with MGA in the LM studies. The IF study in 1 case was negative for C1q, IgG, IgM, IgA, and C3 (Table 2, Fig. 1d and e). In another case, the IF study was not examined.

Discussion
This long-term observational study on transplanted kidneys confirms the existence of cases with predominant but silent C1q deposits in the mesangium who have negative or mild proteinuria with MGA.

Said et al. reported that patients who had predominant mesangial C1q deposits with MGA on their transplanted kidneys, had maintained no proteinuria for a mean follow-up of 1 year [10]. Our study, moreover, demonstrated that patients who had predominant mesangial C1q deposits with MGA on their transplanted kidneys, had maintained

### Table 1 Clinical and pathologic findings at the time when predominant mesangial C1q deposits were detected

| Case No. | Reason for RBx | Laboratory results | LM findings | IF findings | EM findings |
|----------|----------------|--------------------|-------------|-------------|-------------|
|          |                | Up OB sCr [mg/dL]  | IgG IgM IgA C1q C3 | Mes Subend Subep | ARB |
| 1        | Protocol       | (−) (−) 0.7        | MGA         | 2+ 1+ 1+ 2+ 1+ (+) (−) (+) | − |
| 2        | Protocol       | (−) (−) 0.6        | MGA         | 2+ 1+ − 2+ 1+ (+) (−) (−) | losartan potassium 100 mg/day |
| 3        | Protocol       | (−) (−) 1.2        | MGA         | 2+ 1+ − 2+ 1+ (+) (+) (−) | − |
| 4        | Mild proteinuria | (+) (−) 0.7       | MGA         | 2+ 2+ 2+ 2+ 1+ (+) (−) (−) | − |
| 5        | Protocol       | (−) (−) 0.6        | MGA         | 1+ 1+ − 2+ 1+ (+) (−) (+) | losartan potassium 25 mg/day |

Abbreviation: No number, RBx renal biopsy, LM light microscopy, IF immunofluorescent, EM electron microscopy, Up urinary protein, OB occult blood, sCr serum creatinine, MGA minor glomerular abnormality, Mes mesangial deposits, Subend subendothelial deposits, Subep subepithelial deposits

### Table 2 Clinical and pathologic findings 10 years later

| Case No. | Laboratory results | LM findings | IF findings | ARB |
|----------|--------------------|-------------|-------------|-----|
|          | Up OB sCr [mg/dL]  |             |             |     |
| 1        | 1+ − 1.27          | MGA(8 y later) | NA          | candesartan cilexetil 25 mg/day |
| 2        | 1+ − 1.39          | NA          | NA          | losartan potassium 100 mg/day |
| 3        | − − 1.78           | MGA (8 y later) | Negative for C1q, IgG, IgM, IgA and C3 | losartan potassium 25 mg/day |
| 4        | ± − 0.83           | NA          | NA          | valsartan 60 mg/day |
| 5        | − − 0.80           | NA          | NA          | losartan potassium 37.5 mg/day |

Abbreviation: No number, LM light microscopy, IF immunofluorescent, Up urinary protein, OB occult blood, sCr serum creatinine, MGA minor glomerular abnormality, NA not available, ARB angiotensin receptor blocker
negative to mild proteinuria without hematuria even for 10 years follow-up.

**Differences between our eligible cases and previous reports of C1qN**

The age at diagnosis and gender ratio were similar to those of previous reports of C1qN [1, 2, 4]. Pathologically, the LM, IF, and EM findings also corresponded to those in Jennette's reports (Table 1) [1, 2]. EM showed a similar rate of occurrence of subendothelial and subepithelial EDDs in our eligible cases as in those of Jennette's reports [1, 2, 4].

The prevalence of C1qN differs in various reports, ranging from 0.2 to 1.9% in biopsies from children and adults [2, 6]. The 0.01% incidence in our sample population was less than the incidence of C1qN in previous reports. The reason might be that our study was done in cases with transplanted kidneys. Renal graft biopsy is performed repeatedly by protocol, even in patients with normal urinalysis.

No cases showed FSGS or mesangial proliferative glomerulonephritis (MesPGN) in our study. As for IgA deposits, only 1 out of the 5 cases had positive staining, although 9 cases out of 15 exhibited positive staining in Jennette's previously published case series [1, 2]. In this regard, our eligible cases differ from those in previous reports of C1qN. These differences might be related to the negative or mild proteinuria or hematuria observed in our cases.

**Why was normal urinalysis observed in our eligible cases?**

Immune complex deposits are thought to cause nephritis by attracting and activating intrinsic glomerular cells to release local mediators of inflammation [11]. On the other hand, one report suggested that overt C1qN would require additional factors in addition to C1q deposits. Issac et al. suggested that BK polyoma viral infection could trigger C1qN [12], although our eligible cases were not positive for BK polyoma viral infection as assessed by SV40 T antibody staining in any renal graft specimens.

C1q deposits might be only innocent bystanders. Waldherr et al. reported that patients with IgAN are only the tip of the iceberg among patients with IgA deposits in their kidneys because mesangial IgA deposits are found in approximately 4.8% of the general population, whereas IgAN was found in 0.02% of the general population [13]. Thus, the prevalence of predominant but silent C1q deposits would be higher than that of C1qN.

Although C1qN was previously described as MGA, FSGS, and MesPGN in LM [1–5], no eligible cases in the current study presented with FSGS or MesPGN. This might mean that our eligible cases did not have C1qN, but only silent C1q deposits, similar to silent predominant mesangial IgA deposits that present in MGA [13]. This would also explain the reason for the negative to mild proteinuria findings in contrast to previous reports of C1qN [1–5].
Another possibility for why our eligible cases did not experience abnormal urinanalysis is that immunosuppressive therapy against rejection might suppress the inflammation, although Kersnik Levart et al. reported that cyclosporine A and/or mycophenolate mofetil were not effective for some cases of C1qN [14].

ARBs could prevent proteinuria; however, 2 cases did not experience proteinuria before ARBs were administrated. Moreover, in one of the 2 cases, not only C1q deposits but all other deposits were not detected 8 years later. This suggests the existence of cases with predominant but silent C1q deposits in the mesangium.

Conclusion

This long-term observational study on transplanted kidneys confirms that there are cases with predominant but silent C1q deposits in the mesangium who have negative or only mild proteinuria with MGA. This provides a first step towards a better understanding of the role of predominant mesangial C1q deposits.

Additional file

Additional file 1: Pathologic findings. Minor glomerular abnormalities stained with Periodic acid–Schiff stain. Original magnification ×600. Immunofluorescence detection of C1q deposits in mesangial areas (2+ intensity). Electron-dense deposits on mesangial and para-mesangial areas. Minor glomerular abnormality. (PPTX 8948 kb)

Abbreviations

ARB: Angiotensin receptor blocker; C1qN: C1q nephropathy; EDD: Electron-dense deposit; EM: Electron microscopy; FSGS: Focal segmental glomerulosclerosis; IF: Immunofluorescence microscopy; LM: Light microscopy; MesPGN: Mesangial proliferative glomerulonephritis; MGA: Minor glomerular abnormality; SLE: Systemic lupus erythematosus

Acknowledgements

The authors wish to thank Shigeru Horita, Department of Medicine, Kidney Center Tokyo Women’s Medical University, Japan, for his assistance for his valuable technical assistance.

Funding

This study was financially supported in part by the Kawano Masanori Memorial Foundation for the Promotion of Pediatrics and Takeda Science Foundation.

Availability of data and materials

All supporting data for this study are found in the manuscript or is available on Additional file 1.

Authors’ contributions

TK, YA, KM MH and MH designed and registered the study, participated in the data acquisition, and drafted the manuscript. JK and YY checked the pathological findings and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study complies with the Declaration of Helsinki, and was approved by the Ethics Committee of Tokyo Women's Medical University. The written informed consents from each participate are not required for this study. To let the patients notice this study, we have put an announcement on our web site: http://www.twmu.ac.jp/TWMI/ Medicine/Rinshokouza/093/shinyou_kenkyu.html#isyoku_c1q since September 2016.

Consent for publication

Not applicable. It is not required to obtain the consents from participants for publication. To let the patients to notice this study, we have put an announcement on our web site: http://www.twmu.ac.jp/TWMI/Medicine/Rinshokouza/093/shinyou_kenkyu.html#isyoku_c1q since September 2016.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Department of Pediatric Nephrology, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan. 2 Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. 3 Department of Pediatrics, Saitama Medical University, 7-11-1, Moroyama, Saitama, Japan. 4 Department of Pathology, Kawasaki City Tama Hospital, Kawasaki, Kanagawa, Japan. 5 Yamaguchi’s Pathology Laboratory, Chiba, Japan.

Received: 1 November 2016 Accepted: 15 March 2018
Published online: 06 April 2018

References

1. Jennette JC, Higginbotham evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol. 1985;83(3):415–20.

2. Jennette JC, Higginbotham nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6(2):103–10.

3. Iskandar SS, Browning MC, Loertsch WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis. 1991;18(4):459–65.

4. Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, D’Agati VD. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int. 2003;64(4):1232–40.

5. Lau KK, Gaber LW, Delos Santos NM, Wyatt RJ. C1q nephropathy: features at presentation and outcome. Pediatr Nephrol. 2005;20(6):744–9.

6. Vizjak A, Ferluga D, Rozic M, Hvala A, Jurcic V, Juretic J, Jennette JC. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008;19(11):2327–44.

7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

8. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics. 1996;98(4 Pt 1):649–650.

9. Trouw LA, Grolleau KD, Wessels MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest. 2004;114(5):679–88.

10. Said SM, Cornell LD, Valeri AM, Seth S, Fidler ME, Cosio FG, Nasr SH. C1q deposition in the renal allograft: a report of 24 cases. Modern Pathol. 2010; 23(9):1080–8.

11. Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol. 2005;9(3):183–91.

12. Isaac J, Shihab FS. De novo C1q nephropathy in the renal allograft of a kidney pancreas transplant recipient: BK virus-induced nephropathy? Nephron. 2002;92(2):413–6.

13. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposition in the renal allograft: a report of 24 cases. Modern Pathol. 2010; 23(9):1080–8.

14. Kanai T, Kanda RB, Avantijn Cavic M, Ferluga D, Hvala A, Vizjak A. C1Q nephropathy in children. Pediatr Nephrol. 2005;20(12):1756–61.